Table 1.
Patient clinical pathological variables
| Clinical pathological variables | number |
|---|---|
| Age (years) | |
| ≤50 | 69 (53.5 %) |
| >50 | 60 (46.5 %) |
| Tumor size (cm)a | |
| ≤2 | 31 (24.0 %) |
| >2, ≤5 | 74 (57.4 %) |
| >5 | 22 (17.1 %) |
| Unavailable | 2 (1.6 %) |
| Lymph node stage | |
| negative | 65 (50.4 %) |
| positive | 64 (49.6 %) |
| Grade | |
| G1 | 24 (18.6 %) |
| G2 | 30 (23.3 %) |
| G3 | 75 (58.1 %) |
| Clinical stagea | |
| I | 19 (14.7 %) |
| II | 62 (48.1 %) |
| III and IV | 46 (35.7 %) |
| Unavailable | 2 (1.6 %) |
| Histological type | |
| IDC | 101 (78.3 %) |
| ILC | 18 (14.0 %) |
| Others | 10 (7.8 %) |
| Ki-67 LI | |
| Low (≤14 %) | 39 (30.2 %) |
| High (>14 %) | 90 (69.8 %) |
| Chemotherapy | |
| AC | 45 (34.9 %) |
| AC-T | 72 (55.8 %) |
| Others | 10 (7.8 %) |
| None | 2 (1.6 %) |
| Radiotherapy | |
| No | 67 (51.9 %) |
| Yes | 62 (48.1 %) |
| Cohort | |
| FAHHMU | 49 (38.0 %) |
| DLH | 45 (34.9 %) |
| DOGH | 35 (27.1 %) |
Abbreviations: LN, lymph node; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Ki-67 LI, Ki-67 label index; AC, Adriamycin/Cyclophosphamide; AC-T, Adriamycin/Cyclophosphamide-Taxol; FAHHMU, The Fifth Affiliated Hospital of Harbin Medical University; DLG, Daqing Longnan Hospital; DOGH, Daqing Oilfield General Hospital
Note: afor the variable, data for two cases are unavailable from medical records